Annual Operating Expenses
$510.34 M
-$24.06 M-4.50%
31 December 2023
Summary:
Supernus Pharmaceuticals annual total operating expenses is currently $510.34 million, with the most recent change of -$24.06 million (-4.50%) on 31 December 2023. During the last 3 years, it has risen by +$85.12 million (+20.02%). SUPN annual operating expenses is now -4.50% below its all-time high of $534.40 million, reached on 31 December 2022.SUPN Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Expenses
$118.28 M
-$13.92 M-10.53%
30 September 2024
Summary:
Supernus Pharmaceuticals quarterly total operating expenses is currently $118.28 million, with the most recent change of -$13.92 million (-10.53%) on 30 September 2024. Over the past year, it has dropped by -$7.42 million (-5.90%). SUPN quarterly operating expenses is now -22.45% below its all-time high of $152.51 million, reached on 30 September 2022.SUPN Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SUPN Operating Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -5.9% |
| 3 y3 years | +20.0% | -12.3% |
| 5 y5 years | +124.3% | +113.0% |
SUPN Operating Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -4.5% | +20.0% | -22.4% | +5.2% |
| 5 y | 5 years | -4.5% | +124.3% | -22.4% | +113.0% |
| alltime | all time | -4.5% | +2092.1% | -22.4% | +1362.7% |
Supernus Pharmaceuticals Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $118.28 M(-10.5%) |
| June 2024 | - | $132.19 M(+0.5%) |
| Mar 2024 | - | $131.58 M(+4.7%) |
| Dec 2023 | $510.34 M(-4.5%) | $125.70 M(-0.7%) |
| Sept 2023 | - | $126.60 M(-3.6%) |
| June 2023 | - | $131.27 M(+3.5%) |
| Mar 2023 | - | $126.78 M(+12.7%) |
| Dec 2022 | $534.40 M(+25.7%) | $112.44 M(-26.3%) |
| Sept 2022 | - | $152.51 M(+10.9%) |
| June 2022 | - | $137.50 M(+4.2%) |
| Mar 2022 | - | $131.94 M(-2.1%) |
| Dec 2021 | $425.21 M(+45.5%) | $134.84 M(+38.0%) |
| Sept 2021 | - | $97.69 M(+7.4%) |
| June 2021 | - | $90.94 M(-10.6%) |
| Mar 2021 | - | $101.74 M(+26.7%) |
| Dec 2020 | $292.34 M(+28.5%) | $80.33 M(+3.8%) |
| Sept 2020 | - | $77.41 M(+6.3%) |
| June 2020 | - | $72.80 M(+17.8%) |
| Mar 2020 | - | $61.81 M(+11.3%) |
| Dec 2019 | $227.52 M(-8.7%) | $55.52 M(-3.6%) |
| Sept 2019 | - | $57.59 M(-0.8%) |
| June 2019 | - | $58.05 M(+3.0%) |
| Mar 2019 | - | $56.36 M(-21.6%) |
| Dec 2018 | $249.10 M(+32.9%) | $71.89 M(+17.3%) |
| Sept 2018 | - | $61.31 M(+2.0%) |
| June 2018 | - | $60.13 M(+7.9%) |
| Mar 2018 | - | $55.76 M(+11.7%) |
| Dec 2017 | $187.48 M | $49.94 M(-7.2%) |
| Sept 2017 | - | $53.80 M(+17.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2017 | - | $45.90 M(+21.3%) |
| Mar 2017 | - | $37.84 M(-10.6%) |
| Dec 2016 | $148.80 M(+25.9%) | $42.31 M(+26.1%) |
| Sept 2016 | - | $33.54 M(-9.9%) |
| June 2016 | - | $37.23 M(+4.2%) |
| Mar 2016 | - | $35.72 M(+8.2%) |
| Dec 2015 | $118.20 M(+28.2%) | $33.01 M(+3.1%) |
| Sept 2015 | - | $32.03 M(+6.5%) |
| June 2015 | - | $30.07 M(+30.3%) |
| Mar 2015 | - | $23.09 M(-3.1%) |
| Dec 2014 | $92.20 M(+26.6%) | $23.83 M(+7.8%) |
| Sept 2014 | - | $22.10 M(-8.9%) |
| June 2014 | - | $24.26 M(+10.2%) |
| Mar 2014 | - | $22.01 M(+6.7%) |
| Dec 2013 | $72.83 M(+66.9%) | $20.63 M(+12.1%) |
| Sept 2013 | - | $18.40 M(+16.8%) |
| June 2013 | - | $15.76 M(-12.7%) |
| Mar 2013 | - | $18.05 M(+30.5%) |
| Dec 2012 | $43.65 M(+13.2%) | $13.83 M(+11.7%) |
| Sept 2012 | - | $12.38 M(+32.4%) |
| June 2012 | - | $9.35 M(+15.6%) |
| Mar 2012 | - | $8.09 M(-21.4%) |
| Dec 2011 | $38.55 M(-4.2%) | $10.29 M(+3.6%) |
| Sept 2011 | - | $9.93 M(+8.5%) |
| June 2011 | - | $9.15 M(-0.6%) |
| Mar 2011 | - | $9.20 M(-14.5%) |
| Dec 2010 | $40.23 M(+18.6%) | $10.76 M(+25.1%) |
| Dec 2009 | $33.91 M(-2.4%) | $8.60 M |
| Dec 2008 | $34.75 M(+49.3%) | - |
| Dec 2007 | $23.28 M | - |
FAQ
- What is Supernus Pharmaceuticals annual total operating expenses?
- What is the all time high annual operating expenses for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly operating expenses year-on-year change?
What is Supernus Pharmaceuticals annual total operating expenses?
The current annual operating expenses of SUPN is $510.34 M
What is the all time high annual operating expenses for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual total operating expenses is $534.40 M
What is Supernus Pharmaceuticals quarterly total operating expenses?
The current quarterly operating expenses of SUPN is $118.28 M
What is the all time high quarterly operating expenses for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly total operating expenses is $152.51 M
What is Supernus Pharmaceuticals quarterly operating expenses year-on-year change?
Over the past year, SUPN quarterly total operating expenses has changed by -$7.42 M (-5.90%)